3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Rectal Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Liver Neoplasms
1
Laryngeal Diseases
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
3
pembrolizumab
2
napabucasin
2
entinostat
2
Taxes
2
Sunitinib
2
Sorafenib
2
130-nm albumin-bound paclitaxel
2
trametinib
1
siltuximab
1
repotrectinib
1
pralsetinib
1
lutetium Lu 177 dotatate
1
linifanib
1
durvalumab
1
dabrafenib
1
copper dotatate CU-64
1
cobimetinib
1
capmatinib
1
atezolizumab
1
Vemurafenib
1
Pemetrexed
1
Paclitaxel
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Immunotherapy
1
HhAntag691
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
capmatinib
×
Gastrointestinal
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled